WuXi XDC eyes IPO to boost ADC, bioconjugate manufacturing footprint
WuXi XDC is going to list on the Hong Kong Exchange on Nov. 17, with plans to raise approximately HK$3.4 billion ($437.7 million) to expand its manufacturing capabilities.
WuXi XDC is a contract research, development and manufacturing organization (CRDMO) that specializes in antibody-drug conjugates and bioconjugates. Following the IPO, WuXi Biologics will own 50.91% of the CRDMO and WuXi STA will own 33.94%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.